Endovascular treatment for ischaemic stroke produces improvements in functional outcome and other clinical, imaging and safety outcome measures. The treatment effect is similar between men and women, with the latter even having more years of healthy life, as shown in the results of two recent studies.
A renal resistive index (RRI) of ≥0.8 was associated with an increased risk of cardiovascular (CV) events in ASCVD* patients with preserved ejection fraction (EF) but not in those with mid-range or reduced EF, according to a study presented at ESC Asia 2019.
In patients with atrial fibrillation (AF) and stable coronary artery disease (CAD), rivaroxaban monotherapy is noninferior to combination treatment with an antiplatelet therapy in terms of cutting the risk of cardiovascular events and mortality, according to data from the AFIRE trial.
Among Asian patients with heart failure (HF), those who have HFpEF* with a lean diabetic phenotype have the worst prognosis among the five phenotypes identified in Asians which include patients with HFrEF**, according to data from the Asian-HF registry presented at the ESC Asia Congress 2019.
Achieving multifactorial targets for blood pressure (BP), low-density lipoprotein-cholesterol (LDL-C), HbA1c and current smoking greatly benefits patients with and without diabetes mellitus (DM) and is associated with a reduced risk for coronary artery disease (CAD), a study has shown.
Treatment options for patients with heart failure with preserved ejection fraction (HFpEF) remain limited, with benefits that are marginal at best, according to Prof Michel Komajda, past president of the European Society of Cardiology (ESC), at their recently concluded 2019 Asia Congress (ESC Asia 2019).
Coronary artery bypass grafting (CABG) reduces the risk nonfatal myocardial infarction (MI) and major adverse cardiovascular events (MACE) among diabetes mellitus (DM) patients with multivessel disease (MVD), according to a recent study presented at the Asia Congress of the European Society of Cardiology (ESC Asia 2019).
The LAMA* aclidinium bromide was similarly effective in reducing exacerbation rate without raising the risk of MACE** or all-cause mortality regardless of recent history of exacerbations in patients with moderate-to-very severe chronic obstructive pulmonary disease (COPD), according to a subgroup analysis of the phase IV ASCENT-COPD*** trial presented at the CHEST 2019 Annual Meeting.
Low total cholesterol levels appear to carry increased major adverse cardiovascular events (MACE) hazard in older men without ischaemic heart disease (IHD) and not receiving statin therapy but not to those on statins, according to data from the CHAMP (Concord Health and Ageing in Men Project) cohort.
Using blunt needles to administer local anaesthesia in upper blepharoplasty has a lower risk of haemorrhage and need for interventional pain procedures compared with sharp needles, a new randomized clinical trial has found.
In patients with acute ST-segment elevation myocardial infarction (ASTEMI), the risk of new-onset atrial fibrillation (NOAF) appears to be linked with plasma levels of low-density lipoprotein cholesterol (LDL-C) and total cholesterol (TC), a recent China study has found.